结肠癌血管生成相关因子的表达及其意义的研究  

Expression of Angiogenesis Stimulators in Human Colon Cancer

作　　者：吕盈盈[1] 钱家鸣[2] 顾建刚[2] 蒋卫君[2] 

机构地区：[1]复旦大学公共卫生中心 [2]北京协和医院,北京100730

出　　处：《临床消化病杂志》2006年第1期30-34,共5页Chinese Journal of Clinical Gastroenterology

摘　　要：目的研究VEGF配体及其受体在结肠癌发生、发展、转移中的作用,探讨VEGF家族与结肠癌各个时期病理特征的关系。方法在肿瘤标本,癌旁及正常组织标本中,用半定量RT-PCR方法,测定各种标本中VEGF各配体及VEGF受体表达,以研究它们在结肠癌进程中的作用。同时用免疫组化方法,对上述因子进行研究。结果 (1)与正常组织相比,VEGF-A、VEGF-C在肿瘤组织中显著升高(P<0．01);VEGF-B在肿瘤和正常组织中表达相近,而VEGF-D在肿瘤组织中显著降低;(2)VEGF-A、VEGF-B、VEGF-C在有淋巴结转移的肿瘤中明显升高(P<0．01);VEGF-D在有淋巴结转移的肿瘤中下降,但没有统计学差异。(3)VEGFR-1与Duke's分期,淋巴结转移显著相关(P<0．01);VEGFR-2与淋巴结转移显著相关(P<0．01);VEGFR-3与临床病理特征均不相关;VEGFR-1在肿瘤组织比正常组织升高(P<0．01),但VEGFR-2和VEGFR-3表达在肿瘤进程中没有显著升高。结论 VEGF-A、VEGF-B与结肠癌早期发展过程相关,VEGF-C、VEGFR-1与结肠癌进展过程相关,并和VEGF-D、VEGFR-2共同参与转移过程。Objective Our aims were to identify which VEGF family rnelnbers are involved during colon cancer progTession, and to correlate expression with elinieopathological parameters in different cancer stage. Methods We measured the gene expression of VEGF ligands and their receptors in normal colorectal tissues （n=10）, paracanceric tissues （n=14） and in colon cancer tissue （n=22）, using seni-quantitative relative RT-PCR, together with the pattern of their expression by immunohistochemistry. Results （1） VBGF-A and VEGF-C significantly increased in carcinoma comparing with normal tissues; VEOF-D mRNA was significantly more abundant in normal tissues than in carcinoma. （2） A significantly greater amount of VEGF-A, VEGF-B, VEGF-C mRNA were present in carcinoma with metastasis than that without metastasis; while VEGF-D decreased in metastasis. （3） VEGFR-1 was significantly correlated with tumor grade, Duke＇s stage, and lymph node involvement; VEGFR-2 was with lymph node involvement;VEGFR-3 wash＇t correlated with any of the elinicopathologieal variables tested. Conclusion These resuits suggest that VEGF-A and VEGF-B play a role in tumor early development and VEGF-C plays a role in advanced disease, and is involved in metastasis with VEGF-D.

关 键 词：血管生成 VEGF配体 

分 类 号：R735.35[医药卫生—肿瘤]